Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Urine-Derived Epithelial Cells for Corneal Endothelial Cell Dysfunction
NCT07435142Recruiting
- Start
- Feb 2026
- Primary completion
- Nov 2026
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of autologous urinary-derived epithelial cells in corneal endothelial cell dysfunction (FECD). Primary endpoint: Mean change in corneal endothelial cell density at 6 months. Started Feb 2026; status: recruiting.
02
Drugs
autologous urinary-derived epithelial cells
03
Conditions
corneal endothelial cell dysfunction (FECD)
Beyond the preview
Go deeper on NCT07435142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07435142.